Oramed Pharmaceuticals (ORMP) Cash & Equivalents (2010 - 2026)

Oramed Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $13.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 82.28% year-over-year to $13.2 million; the trailing twelve-month figure through Mar 2026 stood at $13.2 million (down 82.28% YoY), and the FY2025 full-year result was $45.9 million, down 15.57% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $13.2 million, down from $45.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $84.8 million in Q2 2024, with the low at $435000.0 in Q2 2025.
• Historically, Cash & Equivalents has averaged $33.1 million across 5 years, with a median of $29.9 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 1152.45% — and 2025, when it sank 99.49%.
• Oramed Pharmaceuticals' Cash & Equivalents stood at $40.5 million in 2022, then tumbled by 77.62% to $9.1 million in 2023, then jumped by 500.99% to $54.4 million in 2024, then retreated by 15.57% to $45.9 million in 2025, then slumped by 71.27% to $13.2 million in 2026.
• The last three Cash & Equivalents figures came in at $13.2 million (Q1 2026), $45.9 million (Q4 2025), and $52.2 million (Q3 2025), per Business Quant data.